GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Price-to-Free-Cash-Flow

Redhill Biopharma (Redhill Biopharma) Price-to-Free-Cash-Flow : N/A (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Price-to-Free-Cash-Flow?

As of today (2024-04-29), Redhill Biopharma's share price is $0.433. Redhill Biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-10.71. Hence, Redhill Biopharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Redhill Biopharma's Price-to-Free-Cash-Flow or its related term are showing as below:

RDHL's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.08
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Redhill Biopharma's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-2.73. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-10.71.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 63.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 36.30% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 14.30% per year.

During the past 13 years, Redhill Biopharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 63.30% per year. The lowest was -38.50% per year. And the median was -2.50% per year.


Redhill Biopharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Redhill Biopharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Price-to-Free-Cash-Flow Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Redhill Biopharma's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Price-to-Free-Cash-Flow falls into.



Redhill Biopharma Price-to-Free-Cash-Flow Calculation

Redhill Biopharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.433/-10.705
=N/A

Redhill Biopharma's Share Price of today is $0.433.
Redhill Biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.71.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Redhill Biopharma  (NAS:RDHL) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Redhill Biopharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.